CA2739611C - Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif - Google Patents

Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif Download PDF

Info

Publication number
CA2739611C
CA2739611C CA2739611A CA2739611A CA2739611C CA 2739611 C CA2739611 C CA 2739611C CA 2739611 A CA2739611 A CA 2739611A CA 2739611 A CA2739611 A CA 2739611A CA 2739611 C CA2739611 C CA 2739611C
Authority
CA
Canada
Prior art keywords
methyl
propyl
dimethylamino
phenol
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2739611A
Other languages
English (en)
Other versions
CA2739611A1 (fr
Inventor
Johannes Bartholomaeus
Iris Ziegler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority claimed from CA2464578A external-priority patent/CA2464578C/fr
Publication of CA2739611A1 publication Critical patent/CA2739611A1/fr
Application granted granted Critical
Publication of CA2739611C publication Critical patent/CA2739611C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une formulation pharmaceutique caractérisée par une libération différée du principe actif. Cette formulation contient du 3-(3-diméthylamino-1-éthyl -2-méthyl-propyl)phénol, ou un de ses sels pharmaceutiquement acceptables, dans une matrice à libération différée du principe actif. Ladite matrice contient entre 1 et 80 % en poids d'au moins un polymère hydrophile ou hydrophobe en tant qu'agent de formation de matrice pharmaceutiquement acceptable et elle présente in vitro la vitesse de dissolution suivante : entre 3 et 35 % en poids (par rapport à 100 % en poids de principe actif) de 3-(3-diméthylamino-1-éthyl -2-méthyl-propyl)phénol libérés après une demi-heure, entre 5 et 50 % en poids libérés après une heure, entre 10 et 75 % en poids libérés après deux heures, entre 15 et 82 % en poids libérés après trois heures, entre 30 et 97 % en poids libérés après six heures, plus de 50 % en poids libérés après douze heures, plus de 70 % en poids libérés après dix-huit heures et plus de 80 % en poids libérés après vingt-quatre heures. La libération lente de l'ingrédient actif est réalisée à l'aide d'une matrice à libération lente, à l'aide d'une matrice normale avec un revêtement qui retarde la libération de l'ingrédient actif ou à l'aide d'un système de libération à entraînement osmotique.
CA2739611A 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif Expired - Lifetime CA2739611C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10152469.2 2001-10-24
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
CA2464578A CA2464578C (fr) 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2464578A Division CA2464578C (fr) 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif

Publications (2)

Publication Number Publication Date
CA2739611A1 CA2739611A1 (fr) 2003-05-01
CA2739611C true CA2739611C (fr) 2013-12-10

Family

ID=7703560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2739611A Expired - Lifetime CA2739611C (fr) 2001-10-24 2002-10-22 Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif

Country Status (4)

Country Link
AR (1) AR104921A2 (fr)
CA (1) CA2739611C (fr)
DE (1) DE10152469A1 (fr)
RU (1) RU2325905C2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20142368A1 (es) * 2008-10-30 2015-02-04 Gruenenthal Chemie Formas de dosificacion del tapentadol novedosas y potentes
WO2021185804A1 (fr) 2020-03-16 2021-09-23 Grünenthal GmbH Comprimé sécable

Also Published As

Publication number Publication date
CA2739611A1 (fr) 2003-05-01
RU2325905C2 (ru) 2008-06-10
RU2004116066A (ru) 2005-05-10
AR104921A2 (es) 2017-08-23
DE10152469A1 (de) 2003-06-26

Similar Documents

Publication Publication Date Title
US11007156B2 (en) Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
JP2013501810A (ja) 医薬組成物
PL213565B1 (pl) Preparat o przedluzonym uwalnianiu zawierajacy lamotrygine
US20090220593A1 (en) Extended release dosage forms of quetiapine
KR20080059212A (ko) 3-(2-디메틸아미노메틸 사이클로헥실) 페놀 지연 제형
US20040197404A1 (en) Extended release oral dosage form
CA2739611C (fr) Medicament contenant du 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, caracterise par une liberation differee du principe actif
US7410965B2 (en) Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
CA2617351C (fr) Formulation a liberation controlee a base de diltiazem et procedes de fabrication
CA2488220C (fr) Medicament contenant du 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol, liberant le principe actif de maniere retardee
WO2003017984A1 (fr) Forme posologique orale a liberation prolongee
AU2002327992A1 (en) a new extended release oral dosage form

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20221024